4//SEC Filing
PetLife Pharmaceuticals, Inc. 4
Accession 0001493152-17-002852
CIK 0001354591operating
Filed
Mar 26, 8:00 PM ET
Accepted
Mar 27, 6:15 AM ET
Size
14.5 KB
Accession
0001493152-17-002852
Insider Transaction Report
Form 4
Salvagno Ralph T
DirectorChief Executive Officer
Transactions
- Purchase
Common Stock
2016-02-12$0.46/sh+540,000$248,400→ 890,000 total(indirect: By LLC) - Award
Employee Stock Option (right to buy)
2016-06-09+2,000,000→ 2,000,000 totalExercise: $0.25From: 2016-06-09Exp: 2019-06-09→ Common Stock (2,000,000 underlying) - Purchase
Common Stock
2016-02-12$0.64/sh+250,000$160,000→ 350,000 total(indirect: By LLC) - Purchase
Common Stock
2015-12-29$0.25/sh+100,000$25,000→ 100,000 total(indirect: By LLC) - Purchase
Common Stock
2016-02-12$0.64/sh+250,000$160,000→ 1,140,000 total(indirect: By LLC) - Award
Common Stock
2017-02-23$0.50/sh+11,160,000$5,580,000→ 12,300,000 total(indirect: By LLC)
Footnotes (3)
- [F1]Adjusted for the issuer's 1-for-5 reverse stock split effected in September 2016.
- [F2]For services valued at $0.50/share.
- [F3]The issuer granted Dr. Salvagno options to purchase 2,000,000 shares of common stock at an exercise price of 50% of the market price or $0.25/share, whichever is higher.
Documents
Issuer
PetLife Pharmaceuticals, Inc.
CIK 0001354591
Entity typeoperating
IncorporatedNV
Related Parties
1- filerCIK 0001354591
Filing Metadata
- Form type
- 4
- Filed
- Mar 26, 8:00 PM ET
- Accepted
- Mar 27, 6:15 AM ET
- Size
- 14.5 KB